TISIDB

Summary
Symbol	B2M
Name	beta-2-microglobulin
Aliases	beta chain of MHC class I molecules; beta-2-microglobin
Chromosomal Location	15q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted Cell surface Note=Detected in serum and urine (PubMed:1336137, PubMed:7554280). ; SUBCELLULAR LOCATION: Note=(Microbial infection) In the presence of M.tuberculosis EsxA-EsxB complex decreased amounts of B2M are found on the cell surface (PubMed:25356553).
Domain	PF07654 Immunoglobulin C1-set domain
Function	Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. Exogenously applied M.tuberculosis EsxA or EsxA-EsxB (or EsxA expressed in host) binds B2M and decreases its export to the cell surface (total protein levels do not change), probably leading to defects in class I antigen presentation (PubMed:25356553).

> Gene Ontology [ TOP ]
Biological Process	GO:0000041 transition metal ion transport GO:0001819 positive regulation of cytokine production GO:0001894 tissue homeostasis GO:0001895 retina homeostasis GO:0001906 cell killing GO:0001909 leukocyte mediated cytotoxicity GO:0001910 regulation of leukocyte mediated cytotoxicity GO:0001912 positive regulation of leukocyte mediated cytotoxicity GO:0001913 T cell mediated cytotoxicity GO:0001914 regulation of T cell mediated cytotoxicity GO:0001916 positive regulation of T cell mediated cytotoxicity GO:0002237 response to molecule of bacterial origin GO:0002250 adaptive immune response GO:0002367 cytokine production involved in immune response GO:0002369 T cell cytokine production GO:0002428 antigen processing and presentation of peptide antigen via MHC class Ib GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002456 T cell mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002474 antigen processing and presentation of peptide antigen via MHC class I GO:0002475 antigen processing and presentation via MHC class Ib GO:0002477 antigen processing and presentation of exogenous peptide antigen via MHC class Ib GO:0002478 antigen processing and presentation of exogenous peptide antigen GO:0002479 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002480 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002481 antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent GO:0002483 antigen processing and presentation of endogenous peptide antigen GO:0002521 leukocyte differentiation GO:0002697 regulation of immune effector process GO:0002699 positive regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002702 positive regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002705 positive regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002708 positive regulation of lymphocyte mediated immunity GO:0002709 regulation of T cell mediated immunity GO:0002711 positive regulation of T cell mediated immunity GO:0002718 regulation of cytokine production involved in immune response GO:0002720 positive regulation of cytokine production involved in immune response GO:0002724 regulation of T cell cytokine production GO:0002726 positive regulation of T cell cytokine production GO:0002819 regulation of adaptive immune response GO:0002821 positive regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002831 regulation of response to biotic stimulus GO:0003254 regulation of membrane depolarization GO:0006457 protein folding GO:0006826 iron ion transport GO:0006898 receptor-mediated endocytosis GO:0006959 humoral immune response GO:0007159 leukocyte cell-cell adhesion GO:0009615 response to virus GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0010039 response to iron ion GO:0010721 negative regulation of cell development GO:0010959 regulation of metal ion transport GO:0010975 regulation of neuron projection development GO:0010977 negative regulation of neuron projection development GO:0015684 ferrous iron transport GO:0019730 antimicrobial humoral response GO:0019731 antibacterial humoral response GO:0019882 antigen processing and presentation GO:0019883 antigen processing and presentation of endogenous antigen GO:0019884 antigen processing and presentation of exogenous antigen GO:0019885 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0030098 lymphocyte differentiation GO:0030100 regulation of endocytosis GO:0030217 T cell differentiation GO:0031341 regulation of cell killing GO:0031343 positive regulation of cell killing GO:0031345 negative regulation of cell projection organization GO:0032091 negative regulation of protein binding GO:0032092 positive regulation of protein binding GO:0032496 response to lipopolysaccharide GO:0032844 regulation of homeostatic process GO:0033077 T cell differentiation in thymus GO:0034341 response to interferon-gamma GO:0034756 regulation of iron ion transport GO:0034758 positive regulation of iron ion transport GO:0042026 protein refolding GO:0042110 T cell activation GO:0042391 regulation of membrane potential GO:0042493 response to drug GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC class I GO:0042742 defense response to bacterium GO:0043270 positive regulation of ion transport GO:0043393 regulation of protein binding GO:0043900 regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0045665 negative regulation of neuron differentiation GO:0045807 positive regulation of endocytosis GO:0046686 response to cadmium ion GO:0048002 antigen processing and presentation of peptide antigen GO:0048259 regulation of receptor-mediated endocytosis GO:0048260 positive regulation of receptor-mediated endocytosis GO:0048871 multicellular organismal homeostasis GO:0050688 regulation of defense response to virus GO:0050690 regulation of defense response to virus by virus GO:0050768 negative regulation of neurogenesis GO:0050792 regulation of viral process GO:0050829 defense response to Gram-negative bacterium GO:0050830 defense response to Gram-positive bacterium GO:0051098 regulation of binding GO:0051099 positive regulation of binding GO:0051100 negative regulation of binding GO:0051607 defense response to virus GO:0051899 membrane depolarization GO:0051961 negative regulation of nervous system development GO:0055072 iron ion homeostasis GO:0055076 transition metal ion homeostasis GO:0060249 anatomical structure homeostasis GO:0060333 interferon-gamma-mediated signaling pathway GO:0060627 regulation of vesicle-mediated transport GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070627 ferrous iron import GO:0070838 divalent metal ion transport GO:0071216 cellular response to biotic stimulus GO:0071219 cellular response to molecule of bacterial origin GO:0071222 cellular response to lipopolysaccharide GO:0071241 cellular response to inorganic substance GO:0071248 cellular response to metal ion GO:0071281 cellular response to iron ion GO:0071346 cellular response to interferon-gamma GO:0071396 cellular response to lipid GO:0071593 lymphocyte aggregation GO:0071594 thymocyte aggregation GO:0072511 divalent inorganic cation transport GO:0097286 iron ion import GO:0097459 iron ion import into cell GO:0097460 ferrous iron import into cell GO:0098542 defense response to other organism GO:0098657 import into cell GO:0098659 inorganic cation import into cell GO:0099587 inorganic ion import into cell GO:1900120 regulation of receptor binding GO:1900121 negative regulation of receptor binding GO:1900122 positive regulation of receptor binding GO:1900390 regulation of iron ion import GO:1903989 regulation of ferrous iron import into cell GO:1903991 positive regulation of ferrous iron import into cell GO:1904432 regulation of ferrous iron binding GO:1904434 positive regulation of ferrous iron binding GO:1904435 regulation of transferrin receptor binding GO:1904437 positive regulation of transferrin receptor binding GO:1990267 response to transition metal nanoparticle GO:2000021 regulation of ion homeostasis
Molecular Function	GO:0001948 glycoprotein binding
Cellular Component	GO:0005769 early endosome GO:0005775 vacuolar lumen GO:0005788 endoplasmic reticulum lumen GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0009897 external side of plasma membrane GO:0010008 endosome membrane GO:0012507 ER to Golgi transport vesicle membrane GO:0030055 cell-substrate junction GO:0030133 transport vesicle GO:0030134 ER to Golgi transport vesicle GO:0030135 coated vesicle GO:0030139 endocytic vesicle GO:0030658 transport vesicle membrane GO:0030659 cytoplasmic vesicle membrane GO:0030662 coated vesicle membrane GO:0030666 endocytic vesicle membrane GO:0030670 phagocytic vesicle membrane GO:0031901 early endosome membrane GO:0031904 endosome lumen GO:0031905 early endosome lumen GO:0042611 MHC protein complex GO:0042612 MHC class I protein complex GO:0043235 receptor complex GO:0044440 endosomal part GO:0045335 phagocytic vesicle GO:0098552 side of membrane GO:0098802 plasma membrane receptor complex GO:1990712 HFE-transferrin receptor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04612 Antigen processing and presentation
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-977225: Amyloid fiber formation R-HSA-983170: Antigen Presentation R-HSA-1236975: Antigen processing-Cross presentation R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1643685: Disease R-HSA-1236974: ER-Phagosome pathway R-HSA-1236977: Endosomal/Vacuolar pathway R-HSA-162906: HIV Infection R-HSA-162909: Host Interactions of HIV factors R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-5663205: Infectious disease R-HSA-168249: Innate Immune System R-HSA-913531: Interferon Signaling R-HSA-877300: Interferon gamma signaling R-HSA-392499: Metabolism of proteins R-HSA-164940: Nef mediated downregulation of MHC class I complex cell surface expression R-HSA-164938: Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters R-HSA-6798695: Neutrophil degranulation R-HSA-164952: The role of Nef in HIV-1 replication and disease pathogenesis

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04612 Antigen processing and presentation

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-977225: Amyloid fiber formation
R-HSA-983170: Antigen Presentation
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1643685: Disease
R-HSA-1236974: ER-Phagosome pathway
R-HSA-1236977: Endosomal/Vacuolar pathway
R-HSA-162906: HIV Infection
R-HSA-162909: Host Interactions of HIV factors
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-5663205: Infectious disease
R-HSA-168249: Innate Immune System
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-392499: Metabolism of proteins
R-HSA-164940: Nef mediated downregulation of MHC class I complex cell surface expression
R-HSA-164938: Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
R-HSA-6798695: Neutrophil degranulation
R-HSA-164952: The role of Nef in HIV-1 replication and disease pathogenesis

Summary
Symbol	B2M
Name	beta-2-microglobulin
Aliases	beta chain of MHC class I molecules; beta-2-microglobin
Chromosomal Location	15q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between B2M and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between B2M and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
25294906	Thyroid Gland Papillary Carcinoma	Promote immunity (infiltration)	Both MHC class I and β2-microglobulin expression was reduced or absent in 76% of PTC specimens and was associated with reduced tumor-infiltrating immune cells, including effector (CD3(+), CD8(+), CD16(+)) and suppressor (FoxP3(+)) populations.
28783722	Melanoma	Promote immunity (T cell function); essential for immunotherapy	For example, loss-of-function mutations in β -2-microglobulin (B2M) and Janus kinases (JAK1 and JAK2) have been reported in patients unresponsive to immunotherapies.; We observed that the reduction in the overall survival of these patients was significantly associated with loss of expression of B2M and TAP1 in tumours biopsied before ipilimumab treatment.; On the basis of our initial optimization of the 2CT-CRISPR assay, we expected that genes directly associated with MHC class I antigen processing and presentation would be enriched in our screens, and found that HLA-A, B2M, TAP1, TAP2, and TAPBP were among the most highly-enriched genes in our screen. Significant resistance was detected in the cells transduced with B2M sgRNAs (72 ± 5%) and with TAP2 sgRNAs (13 ± 2%) against the cytolytic activity of ESO T cells. Loss of expression of these 19 genes within tumours could diminish or extinguish the presentation of tumour antigens (including HLA-A, HLA-F, B2M, TAP1 and TAP2); T cell co- stimulation (ICAM1, CLECL1, LILRA1 and LILRA3); or cytokine production and signalling (JAK2 and STAT1) in the tumour microenvironment that drive infiltration and activation of T cells, and thus serve as a principal mechanism in immune evasion.
27433843	Melanoma	Promote immunity	The B2M truncating mutation led to loss of surface expression of major histocompatibility complex class I.
27785783	Lung Carcinoma	Promote immunity	Tumor tissues obtained from 57 patients diagnosed with lung carcinomas were analyzed for HLA expression and leukocyte infiltration. The HLA-I negative phenotype was produced by a combination of HLA haplotype loss and a transcriptional downregulation of β2-microglobulin (β2-m) and LMP2 and LMP7 antigen presentation machinery genes.
29308317	Colorectal Carcinoma (MMR-deficient)	Promote immunity	Increasing PDCD1 (PD-1)-positive T-cell infiltration was significantly related to an increased likelihood of B2M mutations (OR = 1.81). HLA class II antigen expression status was significantly associated with enhanced overall T-cell infiltration, but not related to PDCD1 (PD-1)-positive T-cells. These results suggest that immune evasion mediated by B2M mutation-induced loss of HLA class I antigen expression predominantly occurs in an environment of activated PDCD1 (PD-1)-positive T cell infiltration.
17541610	Astrocytoma	Promote immunity	Among human WHO grade II-IV astrocytomas, downregulation of LMP2, TAP1 and beta2m correlated with grade of malignancy. Our results support the hypothesis that coordinated downregulation or impaired upregulation of certain HLA class I APM components may serve as a mechanism for astrocytoma cells to evade the host's immune response, even if HLA class I antigen surface expression is not altered.

Summary
Symbol	B2M
Name	beta-2-microglobulin
Aliases	beta chain of MHC class I molecules; beta-2-microglobin
Chromosomal Location	15q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of B2M in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: 3.72; FDR: 0.000150	Sensitive to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: 5.36; FDR: 0.000381	Sensitive to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 2.11	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	B2M
Name	beta-2-microglobulin
Aliases	beta chain of MHC class I molecules; beta-2-microglobin
Chromosomal Location	15q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of B2M in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.276	0.472
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.193	0.973
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.352	0.93
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.665	0.225
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.102	0.968
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.381	0.673
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.156	0.838
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.491	0.878
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.334	0.928
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.943	0.826
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.786	0.909
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.224	0.0552

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of B2M in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	4.1	-4.1	0.561
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	B2M
Name	beta-2-microglobulin
Aliases	beta chain of MHC class I molecules; beta-2-microglobin
Chromosomal Location	15q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of B2M. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	B2M
Name	beta-2-microglobulin
Aliases	beta chain of MHC class I molecules; beta-2-microglobin
Chromosomal Location	15q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of B2M. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by B2M. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	B2M
Name	beta-2-microglobulin
Aliases	beta chain of MHC class I molecules; beta-2-microglobin
Chromosomal Location	15q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of B2M. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	B2M
Name	beta-2-microglobulin
Aliases	beta chain of MHC class I molecules; beta-2-microglobin
Chromosomal Location	15q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of B2M expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	B2M
Name	beta-2-microglobulin
Aliases	beta chain of MHC class I molecules; beta-2-microglobin
Chromosomal Location	15q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between B2M and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	B2M
Name	beta-2-microglobulin
Aliases	beta chain of MHC class I molecules; beta-2-microglobin
Chromosomal Location	15q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting B2M collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting B2M.

ID	Name	Drug Type	Targets	#Targets
DB00254	Doxycycline	Small Molecule	B2M, PADI4	2
DB02740	3-Indolebutyric Acid	Small Molecule	B2M	1
DB04464	N-Formylmethionine	Small Molecule	B2M, CLPP, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, CO ......	23
DB09130	Copper	Small Molecule	A1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......	141

Browse B2M